_id
6919f1e13c536f8df2318616
Ticker
APPH.XETRA
Name
Apontis Pharma AG
Exchange
XETRA
Address
Rolf-Schwarz-Schütte-Platz 1, Monheim am Rhein, Germany, 40789
Country
Germany
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
EUR
Website
https://apontis-pharma.de
Description
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apontis Pharma AG operates as a subsidiary of Zentiva AG.
Last Close
11
Volume
6863
Current Price
11
Change
0
Last Updated
2025-11-16T15:46:41.094Z
Image
https://logo.clearbit.com/apontis-pharma.de
Ipo Date
-
Market Cap
91630000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
2
Strong Buy
0
Buy
0
Hold
0
Sell
1
Strong Sell
0
Current Quarter
2025-06-30
Revenue
26032577
Cost Of Revenue
18624226
Gross Profit
7408351
Operating Expenses
7385392
Operating Income
22958
Interest Expense
-
Pretax Income
819485
Net Income
603748
Eps
0.07247875150060024
Dividends Per Share
-
Shares Outstanding
8330000
Income Tax Expense
215736
EBITDA
1529349
Total Other Income Expense Net
-
Cash
11377689
Short Term Investments
-
Receivables
1862101
Inventories
7771482
Total Current Assets
21011487
Property Plant Equipment
11512
Total Assets
43987137
Payables
2802983
Short Term Debt
-
Long Term Debt
-
Total Liabilities
12366634
Equity
31620503
Depreciation
709860
Change In Working Capital
-4488829
Cash From Operations
-1942272
Capital Expenditures
1537
Cash From Investing
-2134544
Cash From Financing
-
Net Change In Cash
-4076816
PE
137.5
PB
2.8978033651140844
ROE
1.9093560908882443
ROA
1.3725557996647975
FCF
-1943809
Fcf Percent
-0.07466832807216896
Piotroski FScore
2
Health Score
52
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
5
Growth Investing Score
3.5
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
6.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
26032577
Quarters > 0 > income Statement > cost Of Revenue
18624226
Quarters > 0 > income Statement > gross Profit
7408351
Quarters > 0 > income Statement > operating Expenses
7385392
Quarters > 0 > income Statement > operating Income
22958
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
819485
Quarters > 0 > income Statement > net Income
603748
Quarters > 0 > income Statement > eps
0.07247875150060024
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
8330000
Quarters > 0 > income Statement > income Tax Expense
215736
Quarters > 0 > income Statement > EBITDA
1529349
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
11377689
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1862101
Quarters > 0 > balance Sheet > inventories
7771482
Quarters > 0 > balance Sheet > total Current Assets
21011487
Quarters > 0 > balance Sheet > property Plant Equipment
11512
Quarters > 0 > balance Sheet > total Assets
43987137
Quarters > 0 > balance Sheet > payables
2802983
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
12366634
Quarters > 0 > balance Sheet > equity
31620503
Quarters > 0 > cash Flow > net Income
603748
Quarters > 0 > cash Flow > depreciation
709860
Quarters > 0 > cash Flow > change In Working Capital
-4488829
Quarters > 0 > cash Flow > cash From Operations
-1942272
Quarters > 0 > cash Flow > capital Expenditures
1537
Quarters > 0 > cash Flow > cash From Investing
-2134544
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-4076816
Quarters > 0 > ratios > PE
0.07247875150060024
Quarters > 0 > ratios > PB
2.8978033651140844
Quarters > 0 > ratios > ROE
1.9093560908882443
Quarters > 0 > ratios > ROA
1.3725557996647975
Quarters > 0 > ratios > FCF
-1943809
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.07466832807216896
Quarters > 0 > health Score
52
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
25741038
Quarters > 1 > income Statement > cost Of Revenue
20066931
Quarters > 1 > income Statement > gross Profit
5674107
Quarters > 1 > income Statement > operating Expenses
5698808
Quarters > 1 > income Statement > operating Income
-24701
Quarters > 1 > income Statement > interest Expense
35614
Quarters > 1 > income Statement > pretax Income
267473
Quarters > 1 > income Statement > net Income
50773
Quarters > 1 > income Statement > eps
0.006095198079231693
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
8330000
Quarters > 1 > income Statement > income Tax Expense
216700
Quarters > 1 > income Statement > EBITDA
1384558
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
15454505
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
108068
Quarters > 1 > balance Sheet > inventories
5467524
Quarters > 1 > balance Sheet > total Current Assets
23438948
Quarters > 1 > balance Sheet > property Plant Equipment
18333
Quarters > 1 > balance Sheet > total Assets
44373547
Quarters > 1 > balance Sheet > payables
4751419
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
13356793
Quarters > 1 > balance Sheet > equity
31016754
Quarters > 1 > cash Flow > net Income
50773
Quarters > 1 > cash Flow > depreciation
1081473
Quarters > 1 > cash Flow > change In Working Capital
1511680
Quarters > 1 > cash Flow > cash From Operations
905237
Quarters > 1 > cash Flow > capital Expenditures
5597
Quarters > 1 > cash Flow > cash From Investing
-1733567
Quarters > 1 > cash Flow > cash From Financing
126869
Quarters > 1 > cash Flow > net Change In Cash
-701461
Quarters > 1 > ratios > PE
0.006095198079231693
Quarters > 1 > ratios > PB
2.954209844137784
Quarters > 1 > ratios > ROE
0.16369540152396347
Quarters > 1 > ratios > ROA
0.11442177475692894
Quarters > 1 > ratios > FCF
899640
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.034949639559989774
Quarters > 1 > health Score
53
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
22726415
Quarters > 2 > income Statement > cost Of Revenue
16964639
Quarters > 2 > income Statement > gross Profit
5761776
Quarters > 2 > income Statement > operating Expenses
5046550
Quarters > 2 > income Statement > operating Income
715230
Quarters > 2 > income Statement > interest Expense
134826
Quarters > 2 > income Statement > pretax Income
885639
Quarters > 2 > income Statement > net Income
702796
Quarters > 2 > income Statement > eps
0.08436926770708283
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
8330000
Quarters > 2 > income Statement > income Tax Expense
182842
Quarters > 2 > income Statement > EBITDA
2178386
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
16155966
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1445838
Quarters > 2 > balance Sheet > inventories
7039336
Quarters > 2 > balance Sheet > total Current Assets
26967085
Quarters > 2 > balance Sheet > property Plant Equipment
23564
Quarters > 2 > balance Sheet > total Assets
48203590
Quarters > 2 > balance Sheet > payables
5409961
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
17237608
Quarters > 2 > balance Sheet > equity
30965981
Quarters > 2 > cash Flow > net Income
702796
Quarters > 2 > cash Flow > depreciation
1157924
Quarters > 2 > cash Flow > change In Working Capital
-1006642
Quarters > 2 > cash Flow > cash From Operations
-3868176
Quarters > 2 > cash Flow > capital Expenditures
627962
Quarters > 2 > cash Flow > cash From Investing
-664634
Quarters > 2 > cash Flow > cash From Financing
-6126869
Quarters > 2 > cash Flow > net Change In Cash
-10659681
Quarters > 2 > ratios > PE
0.08436926770708283
Quarters > 2 > ratios > PB
2.959053678938833
Quarters > 2 > ratios > ROE
2.269574472709261
Quarters > 2 > ratios > ROA
1.4579743956829772
Quarters > 2 > ratios > FCF
-4496138
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.1978375383886988
Quarters > 2 > health Score
48
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
17905734
Quarters > 3 > income Statement > cost Of Revenue
22868772
Quarters > 3 > income Statement > gross Profit
-4963038
Quarters > 3 > income Statement > operating Expenses
5460026
Quarters > 3 > income Statement > operating Income
-10423060
Quarters > 3 > income Statement > interest Expense
20000
Quarters > 3 > income Statement > pretax Income
-10093340
Quarters > 3 > income Statement > net Income
-7781484
Quarters > 3 > income Statement > eps
-0.9341517406962785
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
8330000
Quarters > 3 > income Statement > income Tax Expense
-2311856
Quarters > 3 > income Statement > EBITDA
-9129460
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
26800000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
846558
Quarters > 3 > balance Sheet > inventories
6600000
Quarters > 3 > balance Sheet > total Current Assets
35100000
Quarters > 3 > balance Sheet > property Plant Equipment
18400000
Quarters > 3 > balance Sheet > total Assets
57500000
Quarters > 3 > balance Sheet > payables
5089944
Quarters > 3 > balance Sheet > short Term Debt
6019578
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
27200000
Quarters > 3 > balance Sheet > equity
30200000
Quarters > 3 > cash Flow > net Income
-7781484
Quarters > 3 > cash Flow > depreciation
943877
Quarters > 3 > cash Flow > change In Working Capital
206362
Quarters > 3 > cash Flow > cash From Operations
-3470891
Quarters > 3 > cash Flow > capital Expenditures
2000344
Quarters > 3 > cash Flow > cash From Investing
-2017078
Quarters > 3 > cash Flow > cash From Financing
6000000
Quarters > 3 > cash Flow > net Change In Cash
512030
Quarters > 3 > ratios > PE
-0.9341517406962785
Quarters > 3 > ratios > PB
3.0341059602649008
Quarters > 3 > ratios > ROE
-25.766503311258276
Quarters > 3 > ratios > ROA
-13.533015652173914
Quarters > 3 > ratios > FCF
-5471235
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.3055577057047759
Quarters > 3 > health Score
26
Valuation > metrics > PE
137.5
Valuation > metrics > PB
2.8978033651140844
Valuation > final Score
50
Valuation > verdict
225.0% Overvalued
Profitability > metrics > ROE
1.9093560908882443
Profitability > metrics > ROA
2.8734187161527407
Profitability > metrics > Net Margin
0.02319201821625266
Profitability > final Score
16
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3910954231183482
Risk > metrics > Interest Coverage
0.0323414062411955
Risk > final Score
60
Risk > verdict
High
Liquidity > metrics > Current Ratio
7.496116458786942
Liquidity > metrics > Quick Ratio
4.723540956188461
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
49.65894039735099
Prev Profitabilities > 0
1
Prev Profitabilities > 1
17
Prev Profitabilities > 2
0
Prev Risks > 0
57
Prev Risks > 1
69
Prev Risks > 2
-2037
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:05:26.800Z
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apontis Pharma AG operates as a subsidiary of Zentiva AG.
Stock Price
€0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Rating:
SELL
$
Analyst Picks
Strong Buy
0
Buy
0
Hold
0
Sell
1
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Apontis Pharma AG
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.